CRESCENT BIOPHARMA, INC. — Director's Dealing 2021

Aug 10, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: GLYCOMIMETICS INC (GLYC)
CIK: 0001253689
Period of Report: 2021-08-06

Reporting Person: Semerjian Harout (Director, Chief Executive Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
No securities beneficially owned	0	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Option (right to buy)	$2.03	2031-08-02	Common Stock (1098400)		Direct
Employee Stock Option (right to buy)	$2.03	2031-08-02	Common Stock (549200)		Direct

Footnotes

F1: 25% of the shares underlying this option will vest on August 3, 2022 and the remaining underlying shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date.

F2: 50% of the shares underlying this option will vest upon FDA approval of the Issuer's product candidate uproleselan as a treatment for relapsed/refractory acute myeloid leukemia and the remainder will vest upon the first commercial sale of uproleselan in the United States or abroad, subject in each case to the Reporting Person's continued service with the Issuer through the applicable vesting date.